AAP
CTXR icon

Arax Advisory Partners’s Citius Pharmaceuticals CTXR Stock Holding History

Arax Advisory Partners’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-84
Closed -$65 – 3916
2025
Q4 		$65 Hold
84
– – ﹤0.01% 3883
2025
Q3 		$104 Buy
+84
New +$117 ﹤0.01% 3493

Other funds holding CTXR

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
AAG
Asset Advisory Group Kinnelon, New Jersey $229M AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Arax Advisory Partners's CTXR Position: Q1 2026 in Review

Arax Advisory Partners sold out of Citius Pharmaceuticals (CTXR) in Q1 2026, closing a stake of 84 shares — an estimated $65 sold.

Arax Advisory Partners first reported a position in CTXR in Q3 2025 and held it in 2 quarters. The position peaked at $104 in Q3 2025. 38 funds tracked by Wall St. Rank hold CTXR as of Q1 2026.

  • Arax Advisory Partners reported no remaining Citius Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Arax Advisory Partners sold 84 Citius Pharmaceuticals shares in Q1 2026, an estimated $65.
  • Arax Advisory Partners first reported a position in Citius Pharmaceuticals in Q3 2025 and held it in 2 quarters.
  • Arax Advisory Partners's Citius Pharmaceuticals position peaked at $104 in Q3 2025.
  • 38 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.